Management of HCV G4 Kasr Alainy

More documents

Recommendations

Info

Gelcaprevir-Pibrentasvir (GP) Surveyor 4 G2, 4-6, Without cirrhosis G/P 8 wks Expedition 4 G1-6, Renal impairment, G/P 12 wks, GT4: n= 20 Hassanein T. et al. AASLD 2016, Gane E. et al. AASLD 2016
Sofosbuvir + Daclatasvir • ALLY-1: SOF+DCV in advanced cirrhosis or post-LTx • 4 G4 patients, SVR-12 100% • ALLY-2: SOF+DCV in HIV coinfection: • 3 G4 patients, SVR12 100% • ANRS CUPILT: Post LTx • 11 G4 patients, SVR12 91% (10/11) • Europe: Advanced Liver Disease, real world: • 19 G4 patients, SVR12 100% Poordad et al. Hepatology. 2016 Wyles DL, et al. N Engl J Med. 2015 Coilly et al., J Hepatol. 2016 Welzel TM, et al. Gut 2016
Page 2 and 3: Management of Patients with HCV Gen
Page 4 and 5: SVR12 (%) Sofosbuvir-RBV • 2 stud
Page 6 and 7: SVR12, % Sofosbuvir-Ledipasvir N=35
Page 8 and 9: SOF-RBV, SOF-LED, SOF-VEL • Integ
Page 10 and 11: SVR12 % Grazoprevir-Elbasvir EBR +
Page 12 and 13: SVR-12 % Sofosbuvir-Simeprevir •
Page 14 and 15: Pariteprevir-ritonavir-Ombitasvir A
Page 16 and 17: Pariteprevir-ritonavir-Ombitasvir A
Page 20 and 21: SVR 12 (%) Outcome of DAA Treatment
Page 22 and 23: http://www.hcvguidelines.org, acces
Page 24 and 25: EASL Recommendations 2016 Retreatme
Page 26 and 27: Conclusion • Treatment of HCV G4

Management of HCV G4 Kasr Alainy

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?